Introduction

This page provides a comprehensive analysis of the known insider trading history of Erik Harris. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Erik Harris has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:RARE / Ultragenyx Pharmaceutical Inc. EVP & Chief Commercial Officer 87,855
US:DNLI / Denali Therapeutics Inc. Director 17,052
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Erik Harris. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by Erik Harris as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-03-04 2025-03-03 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale -15,103 87,855 -14.67 42.10 -635,836 3,698,696
2025-03-04 2025-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 18,443 102,419 21.96
2025-03-04 2025-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 16,813 83,976 25.03
2024-06-04 2024-05-31 4 DNLI Denali Therapeutics Inc.
Common Stock
A - Award 5,967 17,052 53.83
2024-03-05 2024-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale -4,768 67,163 -6.63 53.76 -256,328 3,610,683
2024-03-05 2024-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 957 71,638 1.35
2024-03-05 2024-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 19,400 70,681 37.83
2023-09-06 2023-09-05 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale -6,000 51,281 -10.47 37.96 -227,760 1,946,627
2023-06-21 2023-06-19 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale -305 57,281 -0.53 48.20 -14,701 2,760,944
2023-06-05 2023-06-01 4 DNLI Denali Therapeutics Inc.
Common Stock
A - Award 4,216 11,085 61.38
2023-03-03 2023-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale -3,664 57,344 -6.01 45.25 -165,796 2,594,816
2023-03-03 2023-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 22,000 60,823 56.67
2023-03-03 2023-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 2,663 38,823 7.36
2022-06-22 2022-06-19 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale -295 36,160 -0.81 54.78 -16,160 1,980,845
2022-03-03 2022-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
A - Award 24,900 24,900
2022-03-03 2022-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 14,000 36,317 62.73
2022-03-03 2022-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale -2,713 22,317 -10.84 66.62 -180,740 1,486,759
2022-02-07 2022-02-03 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
A - Award 20,607 20,607
2022-02-07 2022-02-03 4 DNLI Denali Therapeutics Inc.
Common Stock
A - Award 6,869 6,869
2021-10-18 2021-10-14 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale -303 25,030 -1.20 81.14 -24,585 2,030,934
2021-07-08 2021-07-06 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale -375 25,333 -1.46 91.53 -34,324 2,318,729
2021-06-23 2021-06-21 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale X -572 25,708 -2.18 94.96 -54,317 2,441,232
2021-06-23 2021-06-19 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale -437 26,280 -1.64 94.63 -41,353 2,486,876
2021-05-10 2021-05-07 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale X -393 26,717 -1.45 113.67 -44,672 3,036,921
2021-05-10 2021-05-06 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale -307 27,110 -1.12 113.68 -34,900 3,081,865
2021-04-21 2021-04-20 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale X -396 27,417 -1.42 104.28 -41,295 2,859,045
2021-03-03 2021-03-02 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale X -707 27,813 -2.48 138.16 -97,679 3,842,644
2021-03-03 2021-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
A - Award 11,000 11,000
2021-03-03 2021-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale -2,470 28,520 -7.97 138.17 -341,280 3,940,608
2021-03-03 2021-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 4,636 30,990 17.59
2021-03-03 2021-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 5,500 26,354 26.37
2021-02-03 2020-06-03 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale -2,516 20,854 -10.77 74.69 -187,920 1,557,585
2020-10-16 2020-10-14 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
S - Sale -220 23,370 -0.93 88.00 -19,360 2,056,560
2020-07-08 2020-07-06 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
F - Taxes -260 23,590 -1.09 86.75 -22,555 2,046,432
2020-06-22 2020-06-19 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
F - Taxes -303 23,850 -1.25 78.22 -23,701 1,865,547
2020-05-08 2020-05-06 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
F - Taxes -209 24,153 -0.86 66.26 -13,848 1,600,378
2020-04-21 2020-04-19 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
F - Taxes -210 24,362 -0.85 58.57 -12,300 1,426,882
2020-03-03 2020-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
A - Award 22,000 22,000
2020-03-03 2020-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
F - Taxes -824 24,572 -3.24 56.08 -46,210 1,377,998
2020-03-03 2020-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 3,287 25,396 14.87
2020-03-03 2020-03-01 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 7,800 22,109 54.51
2019-10-16 2019-10-14 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 1,208 14,309 9.22
2019-07-09 2019-07-06 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
F - Taxes -260 13,101 -1.95 59.51 -15,473 779,641
2019-06-21 2019-06-19 4 RARE Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
A - Award 12,000 12,000
2019-06-21 2019-06-19 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 3,500 13,361 35.49
2019-06-21 3 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
19,722
2019-06-21 3 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
19,722
2019-06-21 3 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
19,722
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)